AEGiS-FDA: Tentative approval of efavirenz, lamivudine, and tenofovir disoproxil fumarate tablets, 600mg/300mg/300mg Food and Drug AdministrationImportant note: Information in this article was accurate in 2009. The state of the art may have changed since the publication date.
Click here to return to FDA main menu
DonateNow


Tentative approval of efavirenz, lamivudine, and tenofovir disoproxil fumarate tablets, 600mg/300mg/300mg

Food and Drug Administration - September 4, 2009


On September 3, 2009, FDA granted tentative approval for a generic fixed-does combination tablet containing efavirenz, lamivudine, and tenofovir disoproxil fumarate, 600mg/300mg/300mg. This new fixed-dose combination is manufactured by Matrix Laboratories Limited of Hyberdad, India. It is indicated for use alone or in combination with other antiretroviral products for the treatment of HIV-1 infection.

"Tentative approval" means that FDA has concluded that a drug product meets all required quality, safety and efficacy standards, but is not presently eligible for final approval or marketing in the U.S. because of existing patents and/or exclusivity rights. However, tentative approval does make the product eligible for purchase outside the United States under the President's Emergency Plan for AIDS Relief (PEPFAR) <http://www.pepfar.gov/>.

As with all generic applications, FDA conducts an on-site inspection of each manufacturing facility, and of the facilities performing the bioequivalence studies, to evaluate the ability of the manufacturer to produce a quality product and to assess the quality of the bioequivalence data supporting the application prior to granting approval or tentative approval to these applications.

A complete list of all Approved and Tentatively Approved Antiretrovirals in Association with the President's Emergency Plan can be found on the FDA web site: <http://www.fda.gov/InternationalPrograms/FDABeyondOurBordersFore ignOffices/AsiaandAfrica/ucm119231.htm>

Richard Klein

Office of Special Health Issues

Food and Drug Administration

Kimberly Struble

Division of Antiviral Drug Products

Food and Drug Administration
090904
FD090901


SOURCE: Food and Drug Administration (FDA).

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, the Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.

Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .